Aslan Fred was awarded 45,000 Artiva Biotherapeutics shares and 155,000 derivative securities on 2026-09-10. The awards left him with 1,494,765 shares and 155,000 derivative securities, meaning the transactions represented about 3.0% and 100.0% of those respective resulting holdings, giving investors updated insider ownership data.
Key Highlights
- The derivative securities award left Aslan Fred with 155,000 derivative securities.
- The 45,000-share award represented about 3.0% of Fred’s resulting share holding.
- Both transactions carried SEC transaction code A.
Aslan Fred was awarded 45,000 shares of Artiva Biotherapeutics, Inc (NASDAQ: ARTV). on 10 September 2026. Fred is the company’s chief executive officer, and his reported share holding following the award was 1,494,765 shares.
Separate Share and Derivative Awards
A separate transaction awarded Fred 155,000 derivative securities on the same date. His resulting derivative securities holding was 155,000, and the award represented about 100.0% of that holding. The share award represented about 3.0% of his resulting shares. Both transactions were classified with SEC transaction code A. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: What shares did Aslan Fred receive from Artiva Biotherapeutics?
A: Aslan Fred received an award of 45,000 Artiva Biotherapeutics shares on 10 September 2026. His resulting reported share holding was 1,494,765 shares.
Q: What derivative securities did Aslan Fred receive?
A: Fred received 155,000 derivative securities of Artiva Biotherapeutics on 10 September 2026 under SEC transaction code A. Following the transaction, his resulting derivative securities holding was 155,000.
Q: What does transaction code A mean for Aslan Fred’s award?
A: The filing lists SEC transaction code A for both transactions. It reports awards of Artiva Biotherapeutics shares and derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.